Intellectual and Developmental Disabilities and Cancer Symptom Severity: A Matched Retrospective Cohort Study
Psycho-Oncology · 2025
DOI: 10.1002/pon.70199 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Psycho-Oncology, 2025. Verfasst von Rachel Giblon und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Biostatistics, University of Toronto Dalla Lana School of Public Health, Toronto, Canada. Hauptthemen laut MEDLINE: Neoplasms, Intellectual Disability, Developmental Disabilities. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: CIHR, Canadian Cancer Society Emerging Scholar, Canadian Institutes of Health Research.
Abstract (Originalsprache)
Background
Individuals with intellectual or developmental disabilities (IDD) face increased cancer risks and disparities in cancer care accessibility and quality. Despite these concerns, there is limited research on cancer symptomology among individuals with IDD.
Aims
This study explored differences in cancer symptoms between individuals with and without IDD.
Methods
We conducted a matched retrospective study of adults in Ontario, Canada, with and without IDD who underwent cancer symptom screening using the Edmonton Symptom Assessment Scale‐revised (ESAS‐r), a patient‐reported outcome measure, within 5 years of a new primary cancer diagnosis. Using administrative health data, we performed 1:1 hard matching of individuals with cancer and IDD to those without IDD on age at diagnosis, sex, diagnosis year, cancer type, and registration at a regional cancer center. Conditional logistic regression models compared odds of moderate to severe and severe cancer symptoms.
Results
Among 873 matched pairs, individuals with IDD had higher odds of experiencing severe (vs. moderate, mild, or no) cancer‐related symptoms compared to those without IDD. Symptoms included anxiety, depression, drowsiness, pain, shortness of breath, tiredness, and poor well‐being. Largest magnitudes of effect were for anxiety (odds ratio; OR: 2.20; 95% confidence intervals, CI: 1.68, 2.89) and depression (OR: 2.16; 95% CI: 1.54, 3.02). Similar trends were observed for moderate to severe cancer symptoms compared to mild or no symptoms.
Conclusions
Patients with both cancer and IDD report higher symptom severity than those without IDD, emphasizing the importance of tailored interventions and support services to address their unique needs and alleviate symptom burden.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Biostatistics, University of Toronto Dalla Lana School of Public Health, Toronto, Canada.
- ICES, Toronto, Canada.
- Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada.
- Department of Surgery, Sunnybrook Health Sciences Center, Toronto, Canada.
- Department of Public Health Sciences, Queen's University, Kingston, Canada.
- Department of Community Health Sciences, University of Manitoba, Winnipeg, Canada.
ORCID-Profile: Rachel Giblon, Rinku Sutradhar, Julie Hallet, Rebecca Hansford, Christine Kelly, Natalie Coburn, Shahin Shooshtari, Alyson Mahar
Förderung
- CIHR
- Canadian Cancer Society Emerging Scholar
- Canadian Institutes of Health Research
Zitieren
APA
Giblon, R., Sutradhar, R., Hallet, J., Hansford, R., Kelly, C., Coburn, N., Shooshtari, S., & Mahar, A. (2025). Intellectual and Developmental Disabilities and Cancer Symptom Severity: A Matched Retrospective Cohort Study. Psycho-Oncology. https://doi.org/10.1002/pon.70199
Vancouver
Giblon R, Sutradhar R, Hallet J, Hansford R, Kelly C, Coburn N, et al. Intellectual and Developmental Disabilities and Cancer Symptom Severity: A Matched Retrospective Cohort Study. Psycho-Oncology. 2025. doi:10.1002/pon.70199
BibTeX
@article{Giblon2025,
author = {Giblon, Rachel and Sutradhar, Rinku and Hallet, Julie and Hansford, Rebecca and Kelly, Christine and Coburn, Natalie and Shooshtari, Shahin and Mahar, Alyson},
title = {Intellectual and Developmental Disabilities and Cancer Symptom Severity: A Matched Retrospective Cohort Study},
journal = {Psycho-Oncology},
year = {2025},
doi = {10.1002/pon.70199}
}
EUVIMED